lu af82422
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 25, 2018 (NCT03611569)
Timeline
Indications
Mechanism of action
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06706622 | Phase 3 | Dec 3, 2024 | Lundbeck |
| NCT06258720 | Phase 1 | Mar 18, 2024 | Lundbeck |
| NCT05104476 | Phase 2 | Nov 16, 2021 | Lundbeck |
| NCT03611569 | Phase 1 | Jul 25, 2018 | Lundbeck |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lundbeck | For profit | 4 | 4 | 3 | 2018 |
1 organizations
Page 1 / 1